IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS

被引：0
|
作者：
Escobar, Miguel [1 ]
Agrawal, Neha [2 ]
Chatterjee, Sagnik [2 ]
Bhattacharya, Swastik [2 ]
Caicedo, Jorge [3 ]
Bullano, Michael [3 ]
Schultz, Robert G. [3 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Complete HEOR Solut, New Wales, PA USA
[3] Takeda Pharmaceut USA Inc, Lexington, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [21] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Aledort, Louis M.
    Ewenstein, Bruce M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2193 - 2193
  • [22] Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience
    Jimenez-Yuste, Victor
    Lim, Elise
    Mistry, Ketna
    Ventriglia, Giuliana
    Shapiro, Amy D.
    BLOOD, 2023, 142
  • [23] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Oldenburg, Johannes
    Mahlangu, Johnny N.
    Kim, Benjamin
    Schmitt, Christophe
    Callaghan, Michael U.
    Young, Guy
    Santagostino, Elena
    Kruse-Jarres, Rebecca
    Negrier, Claude
    Kessler, Craig
    Valente, Nancy
    Asikanius, Elina
    Levy, Gallia G.
    Windyga, Jerzy
    Shima, Midori
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 809 - 818
  • [24] EMICIZUMAB IS COST-SAVING FOR FINNISH HEMOPHILIA A PATIENTS WITH FACTOR VIII INHIBITORS
    Viita, A. M.
    Conejero, Prada E.
    Laine, J.
    VALUE IN HEALTH, 2023, 26 (12) : S98 - S98
  • [25] AN ITALIAN PHARMACOUTILIZATION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS AFTER SWITCHING TO EMICIZUMAB
    Perrone, V
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Ferrario, M.
    Esposti, L. Degli
    VALUE IN HEALTH, 2024, 27 (12)
  • [26] Hemlibra® (Emicizumab) receives EU Approval for Routine Prophylaxis of Hemophilia A with Inhibitors against Coagulation Factor VIII
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018, 45 (02)
  • [27] A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors
    Castaman, Giancarlo
    Croteau, Stacy E.
    Quon, Doris
    Lee, Lucy
    Polito, Letizia
    Jimenez-Yuste, Victor
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [28] Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors
    Watanabe, Alexandre Hikiji
    Lee, Shaun Wen Huey
    Chai-Adisaksopha, Chatree
    Lim, Ming Y.
    Chaiyakunapruk, Nathorn
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 7 - 13
  • [29] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89
  • [30] Emicizumab for hemophilia A without inhibitors
    Cafuir, Lorraine
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Kempton, Christine L.
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (07) : 515 - 524
12345